PortalPublikationenTargets for therapy in sarcomeric cardiomyopathies

Targets for therapy in sarcomeric cardiomyopathies

Standard

Targets for therapy in sarcomeric cardiomyopathies. / Tardiff, Jil C; Carrier, Lucie; Bers, Donald M; Poggesi, Corrado; Ferrantini, Cecilia; Coppini, Raffaele; Maier, Lars S; Ashrafian, Houman; Huke, Sabine; van der Velden, Jolanda.

in: CARDIOVASC RES, Jahrgang 105, Nr. 4, 01.04.2015, S. 457-70.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Tardiff, JC, Carrier, L, Bers, DM, Poggesi, C, Ferrantini, C, Coppini, R, Maier, LS, Ashrafian, H, Huke, S & van der Velden, J 2015, 'Targets for therapy in sarcomeric cardiomyopathies', CARDIOVASC RES, Jg. 105, Nr. 4, S. 457-70. https://doi.org/10.1093/cvr/cvv023

APA

Tardiff, J. C., Carrier, L., Bers, D. M., Poggesi, C., Ferrantini, C., Coppini, R., Maier, L. S., Ashrafian, H., Huke, S., & van der Velden, J. (2015). Targets for therapy in sarcomeric cardiomyopathies. CARDIOVASC RES, 105(4), 457-70. https://doi.org/10.1093/cvr/cvv023

Vancouver

Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R et al. Targets for therapy in sarcomeric cardiomyopathies. CARDIOVASC RES. 2015 Apr 1;105(4):457-70. https://doi.org/10.1093/cvr/cvv023

Bibtex

@article{3c200717dafb4aec94fce00e9631cbfe,
title = "Targets for therapy in sarcomeric cardiomyopathies",
abstract = "To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.",
author = "Tardiff, {Jil C} and Lucie Carrier and Bers, {Donald M} and Corrado Poggesi and Cecilia Ferrantini and Raffaele Coppini and Maier, {Lars S} and Houman Ashrafian and Sabine Huke and {van der Velden}, Jolanda",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author 2015. For permissions please email: journals.permissions@oup.com.",
year = "2015",
month = apr,
day = "1",
doi = "10.1093/cvr/cvv023",
language = "English",
volume = "105",
pages = "457--70",
journal = "CARDIOVASC RES",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Targets for therapy in sarcomeric cardiomyopathies

AU - Tardiff, Jil C

AU - Carrier, Lucie

AU - Bers, Donald M

AU - Poggesi, Corrado

AU - Ferrantini, Cecilia

AU - Coppini, Raffaele

AU - Maier, Lars S

AU - Ashrafian, Houman

AU - Huke, Sabine

AU - van der Velden, Jolanda

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.

AB - To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.

U2 - 10.1093/cvr/cvv023

DO - 10.1093/cvr/cvv023

M3 - SCORING: Journal article

C2 - 25634554

VL - 105

SP - 457

EP - 470

JO - CARDIOVASC RES

JF - CARDIOVASC RES

SN - 0008-6363

IS - 4

ER -